Glucose Health, Inc. Reports Debt-Free Balance Sheet and Previews New Soluble Fiber Brand

3 days ago

BENTONVILLE, Ark., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), a consumer-health company specializing in soluble-fiber nutrition…

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval

3 days ago

NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression…

RetinalGenix Reports on its Science and Mission in Light of New AI-Driven Retinal Mapping Study

3 days ago

APOLLO BEACH, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company…

Verano Strengthens National Product Portfolio in Industry’s Fastest-Growing Category with Launch of Swift Lifts as Standalone Pre-roll Brand

3 days ago

Swift Lifts feature premium, perfectly portioned cannabis pre-rolls crafted for those who value quality and convenience  CHICAGO, Jan. 14, 2026…

Human Appeal Concludes First-Ever U.S. Winter Coat Drive

3 days ago

Campaign to support families in need on the East Coast, collecting over 2,000 coats across four StatesFAIRFAX, Va., Jan. 14,…

Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to exceed EUR 1 billion in the future

3 days ago

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 14 JANUARY 2026 at 8:30 EET         Inside information: Orion provides outlook for 2026…

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

3 days ago

14 abstracts will be presented across a range of neurological conditions including post‑stroke spasticity, cervical dystonia, blepharospasm and other movement…

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

3 days ago

— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET…

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

3 days ago

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell”…